Xencor (XNCR) announced that it has initiated dosing of healthy volunteers in the first-in-human study of XmAb942, an investigational high-potency extended half-life anti-TL1A antibody. Xencor continues to expect initial data from the ongoing study during the first half of 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XNCR:
Questions or Comments about the article? Write to editor@tipranks.com